Multiple Sclerosis Headlines

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

Researchers sought to compare the safety and efficacy of ozanimod vs interferon β-1a in individuals with relapsing multiple sclerosis.

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.

Cardiovascular Comorbidities Linked to Increased Brain Atrophy in Multiple Sclerosis

Cardiovascular Comorbidities Linked to Increased Brain Atrophy in Multiple Sclerosis

Researchers investigated the association between cardiovascular risk factors and the development of brain atrophy in individuals with multiple sclerosis.

Are Vaccines Associated With Multiple Sclerosis Relapse?

Are Vaccines Associated With Multiple Sclerosis Relapse?

Researchers found there are no associations between vaccinations and multiple sclerosis relapse flares.

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

A cross-sectional study aimed to assess the effect of smoking and alcohol consumption along with the interactions they have on the clinical course of multiple sclerosis.

Switching to Oral Fingolimod From Injectable Treatment Linked to Fewer MS Relapses

Switching to Oral Fingolimod From Injectable Treatment Linked to Fewer MS Relapses

As injectable disease-modifying therapies can be inconvenient for patients with MS, fingolimod offers an oral treatment option that is associated with significantly lower risk for relapse.

AAN: High Fish Intake Linked to Reduced Risk of Multiple Sclerosis

AAN: High Fish Intake Linked to Reduced Risk of Multiple Sclerosis

Compared with consuming fish less than once per month and no supplements, high fish intake was correlated with a significantly reduced risk of multiple sclerosis.

Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis

Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis

Participants who were treated with both doses of fingolimod experienced less overall progression of disability than those receiving placebo.

DMT Discontinuation in Older MS Patients: Clinical Outcomes Examined

DMT Discontinuation in Older MS Patients: Clinical Outcomes Examined

Of the total patients, 178 (29.7%) discontinued DMT during the study period with only 1 documented relapse occurring in the discontinuers.

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

Further research should focus on establishing whether siponimod exerts its effect on the pathogenic processes associated with disease progression or activity, or both.

Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis

Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis

The study was unable to verify whether the findings may be applicable for lesion locations other than those found with brain biopsies.

Combined Exercise Training Increases BDNF in Relapsing-Remitting MS

Combined Exercise Training Increases BDNF in Relapsing-Remitting MS

The effect of 8 weeks of combined exercise training on serum BDNF concentration was examined in patients with relapsing-remitting multiple sclerosis.

Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS

Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS

A cohort study evaluated the effects of smoking on disease activity in interferon beta-treated relapsing-remitting multiple sclerosis.

Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS

Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS

The impact of treatment with dimethyl fumarate and fingolimod on lymphocyte and leukocyte count was evaluated in patients with multiple sclerosis.

Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure

Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure

Risk of multiple sclerosis may be reduced with high sun exposure.

Multiple Sclerosis Drug Zinbryta Withdrawn From the Market

Multiple Sclerosis Drug Zinbryta Withdrawn From the Market

Daclizumab, an interleukin-2 (IL-2) receptor blocking antibody, was approved in May 2016 to treat adults with relapsing forms of MS.

New Glatiramer Acetate Dose Available for Relapsing Multiple Sclerosis

New Glatiramer Acetate Dose Available for Relapsing Multiple Sclerosis

Glatopa 40 mg has been launched for the treatment of relapsing multiple sclerosis.

Prenatal Exposure to Natalizumab in MS Linked to Miscarriage Risk

Prenatal Exposure to Natalizumab in MS Linked to Miscarriage Risk

Natalizumab exposure is associated with an increased risk of spontaneous abortion for pregnant women with multiple sclerosis.

Improved Balance in MS With Vestibular-Focused Rehab

Improved Balance in MS With Vestibular-Focused Rehab

A vestibular-related rehabilitation program is associated with imrpoved outcomes for patients with multiple sclerosis.

Sign Up for Free e-newsletters

CME Focus